On the other hand, SREBP-1-overexpressed HCC tumors resisted to Sorafenib treatment, but were susceptible to Sorafenib and Betulin combinations (Supplementary Fig. 10A, B). This evidence concerns the gene SREBF1 and hepatocellular carcinoma.